OmniAb, Inc. (OABI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.33-8.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
OmniAb is growing revenue quickly, with 2026 guidance raised to $28-33 million. Cash targets also improved to $33-38 million by year-end 2026. The company beat earnings in Q1 2026, showing progress. Its platform accelerates drug discovery, supporting future growth.
OmniAb remains loss-making with negative EPS expected through 2027. Recent earnings misses and negative cash flow raise concerns. Revenue growth may slow below expectations, and cash targets could be missed.
The stock trades about 20% below our fair value near $3. Analysts expect 37% revenue growth in the next year. Our view aligns with this but remains cautious on profitability and cash flow.
Breaks if: Cash falls below $33 million at end of 2026
Increase year-end cash and cash equivalents guidance reflecting improved cash flow and business momentum.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. OABI is currently loss-making but has shown recent momentum and management stability, which supports the long-term thesis.
The market appears to have priced in a justified valuation, with a slight expectations gap. OABI is trading at a premium compared to its peers, reflecting some confidence in its future performance despite current losses.
Management is on track to increase revenue guidance and improve cash position by year-end 2026. However, the company operates in a high-miss-rate industry, which introduces some near-term risk despite a low probability of missing expectations.
The thesis hinges on OABI's ability to maintain its revenue growth and manage costs effectively. Additionally, the performance of sector bellwethers and the overall economic environment will significantly influence OABI's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The partnership with Eli Lilly enhances growth potential and revenue guidance. No new threats have emerged.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Cash and equivalents guidance increased from $30-$35 million in 2026-Q1 to $37-$41 million in 2026-Q2. Actual cash and short-term investments were $52 million at 2026-Q2. Management is delivering improved cash position guidance consistent with stated priorities.
“The Company now expects to end the year with cash and cash equivalents in the range of $37 million to $41 million.”
“The Company now expects to end the year with cash and cash equivalents in the range of $33 million to $38 million.”
“The Company expects to end 2026 with cash and cash equivalents in the range of $30 million to $35 million.”
Breaks if: EPS loss worsens beyond -$0.32 in FY27
Breaks if: Revenue falls below $28 million in FY26
Over the next 1 to 3 years, OABI's performance will depend on its execution against management priorities and external market conditions. Not investment advice.